{"analyses":[{"ciLowerLimit":"-1.5","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"4.5","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.3113","paramType":"Mean Difference (Final Values)","paramValue":"1.50","statisticalMethod":"Chi-squared","testedNonInferiority":false},{"ciNumSides":"TWO_SIDED","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.4315","statisticalMethod":"Cochran-Mantel-Haenszel","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.3","upperLimit":"6.3","value":"3.9"},{"groupId":"OG001","lowerLimit":"3.4","upperLimit":"8.1","value":"5.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"406"},{"groupId":"OG001","value":"404"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"Chemotherapy alone until disease progression, unacceptable toxicity, or patient refusal","id":"OG000","title":"Chemotherapy"},{"description":"Chemotherapy and Bevacizumab until disease progression, unacceptable toxicity, or patient refusal","id":"OG001","title":"Chemotherapy + Bevacizumab"}],"paramType":"NUMBER","populationDescription":"Participants with measurable disease","reportingStatus":"POSTED","timeFrame":"within 6.5 years","title":"Response Rate: Percentage of Participants With Best Overall Response, Defined as Confirmed Complete Response (CR) or Partial Response (PR) According to RECIST Criteria","type":"SECONDARY","unitOfMeasure":"percentage of participants"}